Neurotensin Infusions in Healthy Individuals -

University of Copenhagen9 enrolled

Overview

Neurotensin (NT) is a gut peptide released postprandially from the small intestine. It is known to exert a range of enterogastrone effects and in animal models it reduces food intake when administered by parenteral routes. In this study, after a 1h baseline period, three doses (2.5, 5.0 and 7.5pmol/kg/min) of NT will be administered in sequence each infusion lasting 1h. On a placebo day saline will be infused similarly 1h infusions. During the final infusion (7.5pmol/kg/min) an ad libitum meal will be ingested. During the experiments blood samples will be collected and subjective perceptions recorded using validated visual analogue scales.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

TRIPLE

Enrollment

Conditions

Healthy

Interventions

NeurotensinOTHER

Neurotensin is an endogenous peptide released from the distal small intestine. It will be administered at three doses (2.5, 5.0 and 7.5pmol/kg/min), each for 1h, in sequence.

SalineOTHER

Isotonic saline will serve as a placebo.

Eligibility

Sex: MALEMin age: 18 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Age = or above 18 years * normal haemoglobin levels * male * Informed consent Exclusion Criteria: * Diabetes mellitus (fasting plasma glucose or HbA1c) * Familiy history of diabetes mellitus * Intestinal disease (incl e.g. inflammatory bowel disease and malabsorbtion) * Family history of inflammatory bowel disease * Previous intestinal resection * Body mass index (BMI) over 25 kg/m2 * Smoker * Nephropathy (S-creatinine\> 130 μM) * Liver disease (ALAT and/or ASAT \> 2 × upper normal limit)

Locations (1)

hvidovre Hospital

Hvidovre, Capital, Denmark

Outcomes

Primary Outcomes

Food intake

The amount of food ingested over 30 minutes will be determined.

Time frame: From time point t=190-220 minutes